InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,523.21
(
1.60%
)
US TECH 100
18,851.20
(
3.01%
)
Dow Jones
40,897.79
(
0.38%
)
Brent Oil
81.37
(
3.57%
)
Bitcoin
65,749.03
(
-0.64%
)
Post# of 252753
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: DewDiligence post# 53732

Sunday, 10/21/2007 3:08:27 PM

Sunday, October 21, 2007 3:08:27 PM

Post# of 252753
>Although the EMEA’s Atripla label excludes the treatment-naïve setting, I doubt that this exclusion will have much practical significance in impeding the switch from Truvada+Sustiva to Atripla.<

The impediment is reimbursement.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up